Acurx Pharmaceuticals (ACXP) Set to Announce Quarterly Earnings on Tuesday

Acurx Pharmaceuticals (NASDAQ:ACXP) will announce its earnings results before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the firm earned ($0.26) EPS. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Acurx Pharmaceuticals Price Performance

NASDAQ ACXP opened at $3.85 on Friday. The firm has a market cap of $50.09 million, a PE ratio of -3.41 and a beta of -1.62. Acurx Pharmaceuticals has a one year low of $1.17 and a one year high of $8.82. The stock’s 50 day simple moving average is $3.00 and its 200 day simple moving average is $2.66.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Acurx Pharmaceuticals in a report on Wednesday, September 13th.

Institutional Trading of Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. BlackRock Inc. grew its holdings in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 149.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,699 shares of the company’s stock after purchasing an additional 10,014 shares during the quarter. BlackRock Inc. owned approximately 0.16% of Acurx Pharmaceuticals worth $55,000 at the end of the most recent reporting period. Institutional investors own 11.28% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.